PT-141 10MG
Find your strength. Choose your bundle.
127 in stock
Earn up to $3.25 back on this itemLazarus Pass · 1–5% store credit + free shipping protection · A$19.95/moA closer
look.
PT-141 (Bremelanotide) — also written PT 141 or PT141 — is a synthetic cyclic peptide from the melanocortin family, studied in research as an agonist at central melanocortin receptors (notably MC4R).
In controlled laboratory settings it is used as a reference compound for investigating melanocortin receptor signalling and related neurochemical pathways.
Research details & references
Last reviewed:
Lazarus Labs supplies PT-141 in Australia as a 10 mg lyophilised reference material at ≥ 99 % purity, with a certificate of analysis for every lot. For research use only — not for human or veterinary use.
What is PT-141?
Research context
PT-141 is an analogue within the melanocortin-agonist class and is studied for its activity at central melanocortin receptors. Laboratories use it as a comparison compound in receptor-binding and neurochemical-signalling research. It is supplied strictly as a reference material for that work.
Specifications
- Presentation: 10 mg per vial
- Purity: ≥ 99 %, confirmed by HPLC and LC-MS
- Form: white lyophilised powder
- Solubility: readily soluble in water (H₂O)
- Testing: every batch independently tested by Janoshik (HPLC + LC-MS)
- Documentation: third-party certificate of analysis per lot
- Intended use: in-vitro and laboratory research only
Quality & documentation
Every lot of PT-141 is independently tested by Janoshik Analytical, with a certificate of analysis reporting HPLC purity and LC-MS identity for your exact batch.
Handling & storage
Store sealed and dry at 2–8 °C. After reconstitution, keep refrigerated and follow your laboratory’s own handling and stability procedures. PT-141 is supplied for research use only and is not for human or veterinary use.
Dispatch & supply in Australia
PT-141 ships from within Australia with tracked delivery, and every order includes the matching certificate of analysis.
Read the citation-backed research overview →
Cited research
- Molinoff PB, et al Annals of the New York Academy of Sciences. 2003. PMID: 12851303.
- Dhillon S, Keam SJ Drugs. 2019. PMID: 31429064.
- Sweeney P, et al Nature Reviews Endocrinology. 2023. PMID: 37365323.
Primary literature, verified against PubMed. Cited for scientific reference only — no human-use indication is implied.
The finer
details.
Check the product format, available strengths and intended use.
- Product
- PT-141 10MG
- Intended use
- Laboratory research only
- Documentation
- See COA tab for strength and batch reports
Read the report.
Know the batch.
Compare the product, strength and batch on your vial with the original laboratory document.
Lazarus batch report
- Batch
- LL-PT141-0125
- Report
- #110537
- Tested
- 2026-08-07
- Reported purity
- 99.870%
Reports identify tested batches. The available reports do not establish which batch will be dispatched with your order.
WA dispatch.
Tracked delivery.
Orders are dispatched from Western Australia with tracking. Check the selected product's availability and any pre-order notice before ordering.
Pre-order items follow their stated dispatch estimate. Orders containing pre-order items ship together once everything is available.
Shipping details →Frequently bought together.
You may also like
-
Recovery researchCOA verified
-
Metabolic researchCOA verified
Tirzepatide
Lazarus Labs Tirzepatide is a premium lyophilised research vial available in 10MG and 30MG strength options with ≥99% purity and third-party COA support. Dispatched from Western Australia within 24 hours. Free express shipping over $300 with AusPost tracking.
-
Research blendCOA verified
-
Metabolic researchCOA verified
